RxDoctor Payments DataLook up a doctor →

Douglas Horstmanshof, MD

Cardiovascular Disease · Royal Oak, MINPI 1881688760

Payments from drug & device makers

$807,743in general payments, 2019–2025

Across 789 payments — averaging $1023.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$589K
  • Boehringer Ingelheim$113K
  • Lilly USA, LLC$32K
  • Alnylam Pharmaceuticals Inc.$29K
  • Novartis$23K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$14K
  • plus $7K from 19 others

What the payments were for

  • Consulting fees$143,69735%
  • Speaking & faculty fees$197,96049%
  • Travel & lodging$48,63912%
  • Food & beverage$16,7574%
  • Education$170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$807,743 in reported general payments places this provider in the 95th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$54,529
Medicare patients
244
Services billed
600

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan119$134,508
JardianceEmpagliflozin83$80,346
EliquisApixaban38$39,557
FarxigaDapagliflozin Propanediol18$17,886
XareltoRivaroxaban21$17,500
VascepaIcosapent Ethyl21$8,545
BrilintaTicagrelor13$6,086
Metoprolol Succinate152$3,179
Eplerenone40$2,055
Torsemide77$1,949
Icosapent Ethyl11$1,683
Enoxaparin Sodium12$1,621
Warfarin Sodium136$1,539
Potassium Chloride62$1,533
Carvedilol107$1,321

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$22,946$134,508119 claims
Boehringer IngelheimJardiance$113,130$80,34683 claims
PfizerEliquis$192$39,55738 claims
AstraZenecaFarxiga, Brilinta$15$23,97231 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in Royal Oak

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →